Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Dual ICOS/CD28 antagonist demonstrates efficacy in models of autoimmune disease

Oct. 29, 2018

SpinalCyte presents 12-month data from phase I/II study of CybroCell in degenerative disc disease

Oct. 26, 2018

Phase IIb study of SM-04690 in knee osteoarthritis meets primary endpoints

Oct. 25, 2018

Results from the phase IIb RISE-SSc study of riociguat presented

Oct. 25, 2018

Disruption of actin-binding by PLS3 mutations causes congenital diaphragmatic hernia

Oct. 23, 2018

Topline results from phase IIb study of dapirolizumab pegol in SLE

Oct. 23, 2018

Prdx6 as a new therapeutic target to restore muscle loss in type 2 diabetes-associated sarcopenia

Oct. 23, 2018

Phase II study of rozanolixizumab achieves proof of concept in myasthenia gravis

Oct. 18, 2018

Protecting cartilage in arthritis

Oct. 17, 2018

Phase II results presented for ustekinumab in patients with active systemic lupus erythematosus

Oct. 5, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...